A citation-based method for searching scientific literature


List of co-cited articles
20 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
77
37

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
30
37

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh,[...]. Clin Pharmacol Ther 2012
159
37

SGLT inhibitor adjunct therapy in type 1 diabetes.
Rory J McCrimmon, Robert R Henry. Diabetologia 2018
40
37

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
37


Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M Laffel, David Z Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George,[...]. Diabetes Care 2019
3
66

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J L Heerspink, David Cherney. Diabetes Care 2019
12
25

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
95
25

Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
11
25

Hyperglycemic crises in adult patients with diabetes.
Abbas E Kitabchi, Guillermo E Umpierrez, John M Miles, Joseph N Fisher. Diabetes Care 2009
724
25

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
761
25

Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison.
J A McKnight, S H Wild, M J E Lamb, M N Cooper, T W Jones, E A Davis, S Hofer, M Fritsch, E Schober, J Svensson,[...]. Diabet Med 2015
178
25

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
190
25

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
96
25

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
25

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
134
25

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
25

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
25

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol Ther 2019
8
12

SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
Aparna P Sajja, Amit K Dey, Avirup Guha, Youssef Elnabawi, Aditya A Joshi, Ankur Kalra. J Cardiovasc Pharmacol Ther 2019
6
16

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
David R Matthews, Qiang Li, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Mehul Desai, William R Hiatt, Mark Nehler, Elisa Fabbrini,[...]. Diabetologia 2019
47
12

Type 1 diabetes mellitus.
Anastasia Katsarou, Soffia Gudbjörnsdottir, Araz Rawshani, Dana Dabelea, Ezio Bonifacio, Barbara J Anderson, Laura M Jacobsen, Desmond A Schatz, Åke Lernmark. Nat Rev Dis Primers 2017
279
12

Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.
Thomas Danne, Vijay N Joish, Marion Afonso, Phillip Banks, Sangeeta Sawhney, Pablo Lapuerta, Michael J Davies, John B Buse, Dee Lin, Matthew Reaney,[...]. Diabetes Technol Ther 2021
1
100


Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care.
Emma G Wilmot, Pratik Choudhary, Lalantha Leelarathna, Mike Baxter. Diabetes Obes Metab 2019
13
12

Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures.
Jeremy H Pettus, Jake A Kushner, Virginia Valentine, Richard Wood, Christianne Pang, Sachin Paranjape, Rachele Berria, Antonio Deluzio, Steven E Edelman. Diabetes Technol Ther 2019
4
25

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
38
12

Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin.
Claire Ervin, Vijay N Joish, Emily Evans, Dana DiBenedetti, Matthew Reaney, Ronald Preblick, Rita Castro, Thomas Danne, John B Buse, Pablo Lapuerta. Clin Ther 2019
3
33

Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
Michael Doumas, Konstantinos P Imprialos, Konstantinos Stavropoulos. N Engl J Med 2018
1
100

Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status.
Jong Chul Won, Jae Hyuk Lee, Jae Hyeon Kim, Eun Seok Kang, Kyu Chang Won, Dae Jung Kim, Moon Kyu Lee. Diabetes Metab J 2018
57
12

Sotagliflozin: First Global Approval.
Anthony Markham, Susan J Keam. Drugs 2019
13
12

Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China.
Fiona Bragg, Michael V Holmes, Andri Iona, Yu Guo, Huaidong Du, Yiping Chen, Zheng Bian, Ling Yang, William Herrington, Derrick Bennett,[...]. JAMA 2017
153
12

History of Diabetes Insipidus.
Giovanna Valenti, Grazia Tamma. G Ital Nefrol 2016
6
16


Knockout of Na+-glucose cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase NOS1 in the macula densa and glomerular hyperfiltration.
Panai Song, Winnie Huang, Akira Onishi, Rohit Patel, Young Chul Kim, Charlotte van Ginkel, Yiling Fu, Brent Freeman, Hermann Koepsell, Scott Thomson,[...]. Am J Physiol Renal Physiol 2019
15
12

A new look at painful diabetic neuropathy.
Gordon Sloan, Pallai Shillo, Dinesh Selvarajah, Jing Wu, Iain D Wilkinson, Irene Tracey, Praveen Anand, Solomon Tesfaye. Diabetes Res Clin Pract 2018
40
12

Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
David M Nathan, Peter H Bennett, Jill P Crandall, Sharon L Edelstein, Ronald B Goldberg, Steven E Kahn, William C Knowler, Kieren J Mather, Sunder Mudaliar, Trevor J Orchard,[...]. Diabetologia 2019
19
12

Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.
Peter D Reaven, Nicholas V Emanuele, Wyndy L Wiitala, Gideon D Bahn, Domenic J Reda, Madeline McCarren, William C Duckworth, Rodney A Hayward. N Engl J Med 2019
79
12

A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.
Emily Brown, Surya P Rajeev, Daniel J Cuthbertson, John P H Wilding. Diabetes Obes Metab 2019
31
12

Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.
Yan Zheng, Sylvia H Ley, Frank B Hu. Nat Rev Endocrinol 2018
12

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
Gordon H Guyatt, Andrew D Oxman, Gunn E Vist, Regina Kunz, Yngve Falck-Ytter, Pablo Alonso-Coello, Holger J Schünemann. BMJ 2008
12

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
Theo Vos, Abraham D Flaxman, Mohsen Naghavi, Rafael Lozano, Catherine Michaud, Majid Ezzati, Kenji Shibuya, Joshua A Salomon, Safa Abdalla, Victor Aboyans,[...]. Lancet 2012
12

Type 2 diabetes: a multifaceted disease.
Ewan R Pearson. Diabetologia 2019
27
12

Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk.
Ele Ferrannini, Anna Solini. Nat Rev Endocrinol 2017
5
20

Accounting for oxygen in the renal cortex: a computational study of factors that predispose the cortex to hypoxia.
Chang-Joon Lee, Bruce S Gardiner, Jennifer P Ngo, Saptarshi Kar, Roger G Evans, David W Smith. Am J Physiol Renal Physiol 2017
25
12

Basal renal O2 consumption and the efficiency of O2 utilization for Na+ reabsorption.
Roger G Evans, Gerard K Harrop, Jennifer P Ngo, Connie P C Ow, Paul M O'Connor. Am J Physiol Renal Physiol 2014
36
12

Diffusive oxygen shunting between vessels in the preglomerular renal vasculature: anatomic observations and computational modeling.
Bruce S Gardiner, Sarah L Thompson, Jennifer P Ngo, David W Smith, Amany Abdelkader, Brad R S Broughton, John F Bertram, Roger G Evans. Am J Physiol Renal Physiol 2012
28
12



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.